Turnstone rejigs staff and exec team, eases preclinical work as cash runs low
Just over a year after going public, Turnstone Biologics is axing staff, adjusting its leadership team and changing its pipeline focus to extend its cash runway for another two years. The San Diego...
View ArticleClik here to view.
Perspective’s early data on lead-based radiopharma asset suggest lower dose...
In early-stage trials called dose escalation studies, drug developers usually want to test progressively higher doses of their therapies. Not Perspective Therapeutics. The radiopharma biotech announced...
View Article#CPHI24: European drugmakers look to reshore manufacturing but warn of price...
As European manufacturers localize their supply chains and production, they are also warning that drug prices could creep up if the European Commission doesn’t provide more regulation on drug...
View ArticleTeva to pay $450M to settle allegations of kickbacks and generic drug...
Generics giant Teva Pharmaceuticals will pay $450 million over six years to settle two allegations that the company violated the Anti-Kickback Statute and the False Claims Act, the Department of...
View ArticleClik here to view.
Sanofi lands on private equity firm CD&R as potential buyer of consumer...
Sanofi has chosen US private equity firm Clayton, Dubilier & Rice to advance acquisition talks for its consumer health unit, the pharma confirmed Friday. The company says it entered into...
View ArticleStealth BioTherapeutics CEO discusses surprise adcomm support for ultra-rare...
This week, Stealth BioTherapeutics CEO Reenie McCarthy faced a seemingly insurmountable roadblock with the company’s drug for the ultra-rare, fatal mitochondrial disease Barth syndrome. FDA reviewers...
View ArticleClik here to view.
Valneva and Pfizer eye 2027 launch for partnered Lyme disease vaccine
Valneva is eyeing a 2027 launch for its Pfizer-partnered Lyme disease vaccine, CEO Thomas Lingelbach said Thursday during the company’s investor day. Pfizer has sole commercial responsibility for the...
View ArticlePfizer hemophilia drug marstacimab is approved by FDA
Whew. Pfizer — after a week in which it began a showdown with an activist investor, was betrayed by and then reunited with two former top executives, and ended work on an RSV drug — finally has some...
View ArticlePfizer's situation with Starboard; Meet Endpoints' 2024 Women in Biopharma;...
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add...
View ArticleEli Lilly obesity drug may go back on shortage, FDA says, in win for...
The FDA said it will reconsider the removal of Eli Lilly’s GLP-1 drug tirzepatide from its official shortage list, after a trade group representing large compounding pharmacies challenged the move. A...
View ArticlePfizer details results from failed Phase 3 trial of Duchenne muscular...
The full results from Pfizer’s pivotal study of its Duchenne muscular dystrophy gene therapy show patients saw no significant functional benefit one year after receiving the therapy despite the...
View ArticleClik here to view.
GSK touts data from two late-stage trials with long-acting drug in chronic...
GSK announced another batch of positive data from its respiratory program with the investigational drug depemokimab, this time in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). Both...
View ArticleTPG and Blackstone working on bid to buy eye care company Bausch + Lomb — report
Private equity firms TPG and Blackstone are working on a potential deal to buy Brent Saunders-led eye care company Bausch + Lomb, the Financial Times reports. Citing “people familiar with the matter,”...
View ArticleEli Lilly reveals £279M investment in the UK through new government deal
Eli Lilly plans to invest £279 million ($364 million) in the UK as part of a new government partnership in which the drugmaker will bring its Gateway Labs overseas for the first time. The...
View ArticleNovartis used a PRV to speed Kisqali's latest indication, FDA says
Novartis used one of its priority review vouchers (PRV) to speed the September approval of Kisqali in early breast cancer, the FDA said Monday. The FDA did not disclose where this PRV came to Novartis...
View ArticleNovo Nordisk files 18 lawsuits against GLP-1 compounders in 44 days
Novo Nordisk filed suit against another semaglutide compounder on Friday, bringing its total number of cases to 50. Both Novo Nordisk and Eli Lilly have launched legal campaigns against medical spas,...
View ArticleClik here to view.
Forbion raises €2.1B for two new biotech funds after series of company exits
Dutch biotech investor Forbion has raised two new funds to put into biotech companies, just 18 months after its last major raise and following a series of successful exits in its portfolio. The new...
View ArticleBiotech tools company Nuclera raises $75M for protein manufacturing tech
Protein production company Nuclera has raised a $75 million Series C to continue to bring its manufacturing platform to market next January after a soft launch in May. “This is a perfect time to start...
View ArticleClik here to view.
Seraxis gets green light for stem cell-derived therapy for diabetes, aiming...
Stem cell biologist William Rust has been quietly working on a cure for diabetes for more than a decade. Later this year, surgeons will implant his company’s pancreatic organoids in people with type 1...
View ArticleTolerance Bio emerges from stealth with $17.2M to advance therapies developed...
Tolerance Bio has launched with an oversubscribed $17.2 million seed round and a goal to develop therapies for immune-mediated diseases, from cancer to transplant rejection, using the thymus. The...
View Article